InMed Pharmaceuticals CEO Eric Adams' 2023 pay falls 22% to $368K
InMed Pharmaceuticals reports 2023 executive compensation
By ExecPay News
Published: October 27, 2023
InMed Pharmaceuticals reported fiscal year 2023 executive compensation information on October 27, 2023.
In 2023, five executives at InMed Pharmaceuticals received on average a compensation package of $243K, a 27% decrease compared to previous year.
Average pay of disclosed executives at InMed Pharmaceuticals
Eric A. Adams, Chief Executive Officer, received $368K in total, which decreased by 22% compared to 2022. 76% of Adams' compensation, or $278K, was in salary. Adams also received $70K in bonus and $20K in option awards.
Michael Woudenberg, Chief Operating Officer, received a compensation package of $297K, which decreased by 10% compared to previous year. 81% of the compensation package, or $240K, was in salary.
Alexandra Mancini, Senior Vice President, Clinical & Regulatory Affairs, earned $285K in 2023, a 2% decrease compared to previous year.
Eric Hsu, Senior Vice President, Preclinical Research & Development, received $261K in 2023, which decreases by 8% compared to 2022.
Jonathan Tegge, Chief Financial Officer, earned $2.1K in 2023.
InMed Pharmaceuticals' fiscal year ends on June 30.
Related executives
Eric Adams
InMed Pharmaceuticals
Chief Executive Officer
Michael Woudenberg
InMed Pharmaceuticals
Chief Operating Officer
Alexandra Mancini
InMed Pharmaceuticals
Senior Vice President, Clinical & Regulatory Affairs
Jonathan Tegge
InMed Pharmaceuticals
Chief Financial Officer
Eric Hsu
InMed Pharmaceuticals
Senior Vice President, Preclinical Research & Development
You may also like
Source: SEC filing on October 27, 2023.